Sawtooth Solutions LLC lessened its stake in shares of Oncorus, Inc. (NASDAQ:ONCR – Get Rating) by 52.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,748 shares of the company's stock after selling 40,588 shares during the quarter. Sawtooth Solutions LLC's holdings in Oncorus were worth $31,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ONCR. Millennium Management LLC purchased a new stake in shares of Oncorus during the second quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 1,144.9% during the first quarter. Renaissance Technologies LLC now owns 175,532 shares of the company's stock worth $312,000 after acquiring an additional 161,432 shares during the period. Private Advisor Group LLC acquired a new position in Oncorus during the first quarter worth $112,000. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the first quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Oncorus by 35.1% during the second quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after acquiring an additional 30,668 shares during the period. Hedge funds and other institutional investors own 63.69% of the company's stock.

Oncorus Stock Up 3.0 %

ONCR opened at $0.28 on Friday. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.24. The firm has a market cap of $7.36 million, a P/E ratio of -0.10 and a beta of 2.24. Oncorus, Inc. has a 52 week low of $0.27 and a 52 week high of $5.76. The business's fifty day simple moving average is $0.54 and its 200 day simple moving average is $1.01.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Chardan Capital lowered Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday, November 30th. HC Wainwright lowered Oncorus from a "buy" rating to a "neutral" rating in a report on Tuesday, December 6th. Finally, Piper Sandler lowered Oncorus from an "overweight" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.00 in a report on Wednesday, November 30th.

Insider Activity at Oncorus

In related news, major shareholder James E. Flynn sold 99,718 shares of the stock in a transaction on Monday, December 19th. The stock was sold at an average price of $0.29, for a total transaction of $28,918.22. Following the sale, the insider now owns 332,725 shares of the company's stock, valued at $96,490.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 118,704 shares of company stock valued at $35,123 over the last quarter. Insiders own 15.90% of the company's stock.

Oncorus Profile

(Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Recommended Stories

• Get a free copy of the StockNews.com research report on Oncorus (ONCR)
• MarketBeat: Week in Review 12/19 – 12/23
• These Steelmakers Deserve A Place On Your 2023 Watch List
• Inflation Cools, Where Does The S&P 500 Go Now
• Cintas Beats Inflation With Operating Leverage
• Your Decision to Buy Palantir May Simply Be a Matter of Time

Want to see what other hedge funds are holding ONCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oncorus, Inc. (NASDAQ:ONCR – Get Rating).

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.